CORT (63) ARWR (58) TGTX (63) PTGX (65) ⌘ Pro Terminal →

Cytokinetics Incorporated (CYTK) — RQD Stock Rating Cockpit

$62.99 -0.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $62.81

Cytokinetics Incorporated (CYTK) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $8.76B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CYTK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CYTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cytokinetics Incorporated (NASDAQ: CYTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $62.99 (-0.50% 1D, market cap $8.76B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CYTK ranks #853 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CYTK compare to CORT and ARWR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYTK carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CORT (Corcept Therapeutics Incorporated) holds a C grade (63/100 RQD, P/E 93.2x, ROIC 4.8%, cap $8.77B) and ARWR (Arrowhead Pharmaceuticals Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 11.1%, cap $8.46B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CYTK?

▼

Per CYTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001061983), Cytokinetics Incorporated generated $88.0M in revenue (+376.6% YoY), -$785.0M in net income, and -$534.8M in free cash flow against $1.42B in total assets and $246.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $62.81 (-0.28%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CYTK)Realized 20D OHLCV Swing Band: ±6.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY CYTK SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 0.45 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (25% of score)

20D Institutional Volume Accumulation (±6.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$63.43-0.9% Next Q

Q2 (-2Q)

Grade E$62.86-2.5% Next Q

Q3 (-1Q)

Grade E$61.28+2.8% Next Q

Current

Grade E$62.99-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CYTK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CYTK currently carries a cautious 28/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($66.67) and Max Pain ($66.14) forces dealer call-delta covering toward $92.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CYTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CYTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4630 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.45>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE16% OF RANGE

L: $58$62.99H: $88

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CYTK

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 42.0% gross margin and -6.08% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 0.45 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (28)

12/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like CYTK

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CYTK)

✓Walkthrough of CYTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CYTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.63%▼ DESCENDING CHANNEL

2026-11-03O $63.31H $63.31L $62.99C $62.99VOL 1.26M

RES: $69.55SUP: $58.22SMA50: $66.67SMA200: $70.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CYTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CYTK Butterfly Map → + Track CYTK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

23.9%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CYTK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CYTK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CYTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CYTK)

Health Care Rank #853 of 1016 ⚔️ CORT vs CYTK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CYTK vs. CORT, ARWR, TGTX, PTGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytokinetics Incorporated (CYTK) ranks #853 by composite RQD confidence (28/100, grade E) and #123 by equity capitalization ($8.76B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with CYTK at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CYTK ACTIVE Cytokinetics Incorporated	E	28/100	—	—	-35.0%	-0.50%	$8.76B	Benchmark Subject
CORT Corcept Therapeutics Incorporated	C	63/100	93.2x	96.0%	4.8%	-5.62%	$8.77B	/cort-vs-cytk →
ARWR Arrowhead Pharmaceuticals Inc.	D+	58/100	—	—	11.1%	-0.97%	$8.46B	/arwr-vs-cytk →
TGTX TG Therapeutics Inc.	C	63/100	19.9x	83.7%	12.0%	+5.34%	$9.36B	/tgtx-vs-cytk →
PTGX Protagonist Therapeutics Inc.	C	65/100	—	—	-16.7%	+0.35%	$9.37B	/ptgx-vs-cytk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001061983

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytokinetics Incorporated (CYTK) reported GAAP revenue of $88.0M (+376.6% vs. FY2024 revenue of $18.5M , and +1069.2% cumulative change since FY2023) , GAAP net income of -$785.0M, operating cash flow of -$510.0M, and free cash flow of -$534.8M (-33.8% YoY). On the balance sheet, CYTK closed FY2025 with $1.42B in total assets against $246.4M in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$88.0M	-$785.0M	-$510.0M	-$534.8M	$1.42B	$246.4M
FY2024 (FY)	2024-12-31	$18.5M	-$589.5M	-$395.9M	-$399.8M	$1.40B	$93.2M
FY2023 (FY)	2023-12-31	$7.5M	-$526.2M	-$414.3M	-$414.7M	$4.84B	$1.13B

3. CYTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CYTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CYTK compare to CORT and ARWR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CYTK?

Where is CYTK trading relative to its 50-day, 200-day, and 52-week technical levels?

CYTK last traded at $62.99 (-0.50% on volume of 1,257,257 shares), positioning the stock -5.52% below its 50-day simple moving average ($66.67) and -10.12% below its 200-day simple moving average ($70.08). Across its 52-week range of $58.05 to $88.31, CYTK sits at the 16.3% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($58.90 to $67.08).

CYTK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CYTK stock right now?

Cytokinetics Incorporated (CYTK) currently earns a Roarable Rating of E (Strong Sell — SELL) with 28/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CYTK's 12-month price target and RQD AI Jury consensus?

CYTK's 12-month base price target is $54.49 (range $42.5 to $92.73), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CYTK RQD Cockpit CYTK 12M Forecast CYTK Earnings & Move CYTK Dividends & DRIP CYTK Insiders & 13F CYTK Whale Options CYTK Profit Sankey CYTK News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CYTK — Cytokinetics Incorporated: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:17:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CYTK scores 28 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 3 / 20. Per the RQD rating, this reflects ROIC of -35% and FCF yield of -6.08%. For a prospective investor, this means the business is not currently generating returns on invested capital or positive free cash flow to shareholders; valuation support must come from elsewhere.
Whale 13F Flow: 7 / 20. The RQD rating describes institutional accumulation and options positioning as a modest contributor. Institutional holder detail is not itemized in the source data, so the composition of this score cannot be traced further.
Insider Conviction: 5 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow contributes a weak signal. A prospective investor should treat insider signal as a limited confirmation rather than a positive catalyst.
Macro Regime Fit: 5 / 20. Per the RQD rating, beta is 0.87 with sector sensitivity noted. The lower-than-market beta offers some dampening of broad-market swings, but the score reflects limited alignment with the prevailing regime.
Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 0.45, Piotroski F is 5/9, and Debt/Equity is 0.85. The Altman Z reading sits in a distress-range zone, which is the primary driver of the forensic risk label.

Taken together, the pillars indicate that the stock's weakest components are cash generation and balance sheet resilience. Upside arguments would need to rest on the sheer scale of market capitalization and on positive catalysts rather than on current fundamentals. The valuation tradeoff is that forward P/E of 31 is quoted alongside negative trailing EPS, meaning earnings-based valuation depends on expectations not reflected in trailing results. Investors evaluating this name should weigh the RQD's forensic warning heavily against any narrative-driven upside.

Business

Cytokinetics Incorporated (CYTK) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not itemize specific products, customers, or the revenue model. Reported revenue across the three periods in the SEC financials rose from $7.5M to $18.5M to $88.0M, but the source data does not identify the revenue drivers.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$88.0M	$-612.3M	$-785.0M	N/A	$-534.8M	$122.5M	$246.4M
FY 2024	$18.5M	$-536.2M	$-589.5M	N/A	$-399.8M	$94.9M	$93.2M
FY 2023	$7.5M	$-496.2M	$-526.2M	N/A	$-414.7M	N/A	$1132.8M

Per the market data, operating margin and net margin are each -60%, and gross margin is 0%. ROIC is -35%. Per the RQD rating, the Altman Z-Score is 0.45 and the Piotroski F-Score is 5/9, with Debt/Equity of 0.85. The balance sheet reflects debt of $246.4M against cash of $122.5M in FY 2025, and cash-flow burn persisted in each reported period.

Recent Catalysts & News Wire Analysis

The recent news feed contains six items, all rated YELLOW and labeled MARKET WIRE, with no distinct catalyst specified beyond the headlines. Items reference: a market-data and institutional positioning report from Yahoo Finance Singapore; a similar report from Yahoo Finance Australia; a proposed share sale of $1.42M drawing on Robert Blum's stock options per Stock Titan; a Yahoo Finance piece describing the stock as hard to pin down following "strong heart drug updates"; a Yahoo Finance piece on fresh attention; and a BofA Securities price target adjustment to $81 from $85 with a Neutral rating. Risk watch items include the proposed insider share sale and the mixed-signal framing of the market commentary. The Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.

Open Questions

What are the specific products, indications, and revenue drivers behind the rise from $7.5M to $88.0M in reported revenue?
What is the cash runway, given FY 2025 cash of $122.5M against negative free cash flow of $-534.8M?
What does the forward P/E of 31 assume about earnings trajectory, given negative trailing EPS?
Which institutional holders account for the 13F accumulation reflected in the RQD whale pillar, and at what magnitude?
What is the scope and timing of the proposed insider share sale, and how does it relate to the insider conviction score?

CYTK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cytokinetics Incorporated (CYTK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CYTK Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 18h ago

Cytokinetics, Incorporated (CYTK) stock price, news, quote and history

Yahoo Finance Singapore report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options.

Stock Titan report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates